Prosecution Insights
Last updated: November 04, 2026
Application No. 18/557,760

PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE

Final Rejection §103§112§DOUBLEPATENT
Filed
Oct 27, 2023
Priority
Apr 29, 2021 — provisional 63/181,852 +2 more
Examiner
NEAGU, IRINA
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ústav Organické Chemie A Biochemie Av Cr V V I
OA Round
2 (Final)
47%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 47% of resolved cases
47%
Career Allowance Rate
337 granted / 720 resolved
-13.2% vs TC avg
Strong +57% interview lift
Without
With
+57.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
62 currently pending
Career history
786
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
39.5%
-0.5% vs TC avg
§102
11.5%
-28.5% vs TC avg
§112
24.6%
-15.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 720 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION The amendment dated 13 August 2026, in which claims 1, 4, 5, 26-27, 33, 35, 37, 45, 51, 52, 54, 65 have been amended, and claims 8, 23, 39, 43, 62, 63 have been cancelled, is acknowledged. Claims 1, 4-5, 26-27, 33, 35, 37, 45, 51-52, 54-55, 65 are pending in the instant application. Claims 54-55 are withdrawn, as being drawn to a non-elected invention. Claims 1, 4-5, 26-27, 33, 35, 37, 45, 51-52, 65 are examined herein. Response to arguments of 13 August 2026 In view of Applicant’s amendment of 13 August 2026, all the objections and rejections to claims 8, 23, 39, 43, 62, 63 are herein withdrawn. Claims 8, 23, 39, 43, 62, 63 have been cancelled. In view of Applicant’s amendment of 13 August 2026, the objection to claims 54-55 is herein withdrawn. The status indicators have been corrected. In view of Applicant’s amendment of 13 August 2026, the objections to claim 1 are herein withdrawn. Applicant has deleted the structures on pages 3-5, claim 1. In view of Applicant’s amendment of 13 August 2026, the rejection of claims 1, 4-5, 23, 26-27, 33, 35, 37, 45, 52, 65 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite, is herein withdrawn. Applicant has amended claim 1 to recite PNG media_image1.png 604 672 media_image1.png Greyscale . New rejections to the claims are made under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, based on Applicant’s amendment of 13 August 2026. In view of Applicant’s amendment of 13 August 2026, the rejection of claims 5, 51 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite, is herein withdrawn. Applicant’s argument (Remarks of 13 August 2026, page 17, paragraph 4) that the term “C1-C6 alkyl encompasses -CD3” is not persuasive. A modified rejection to claim 5 is made below, based on Applicant’s amendment of 13 August 2026. In view of Applicant’s amendment of 13 August 2026, the rejection of claim 51 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite, is herein withdrawn. Applicant has amended claim 1 to recite that R7a is selected from PNG media_image2.png 30 242 media_image2.png Greyscale . In view of Applicant’s amendment of 13 August 2026, the rejection of claims 1, 4-5, 23, 26, 37 under 35 U.S.C. 102(a)(1) over Abo-Ghalia; the rejection of claims 1, 4-5, 23, 26, 45, 52 under 35 U.S.C. 102(a)(1) and 102(a)(2) over Slusher (WO 2017/023774); and the rejection of claims 1, 4-5, 23, 26, 45, 52 under 35 U.S.C. 102(a)(1) and 102(a)(2) over Slusher (WO 2019/071110), are herein withdrawn. Applicant has amended claim 1 to recite that R7a is selected from PNG media_image2.png 30 242 media_image2.png Greyscale . In view of Applicant’s amendment of 13 August 2026, the rejection of claims 1, 4-5, 23, 26-27, 33, 35, 37, 51-52, 65 under 35 U.S.C. 103 over Slusher (WO 2017/023774) is herein withdrawn. Applicant has amended claim 1 to recite that R7a is selected from PNG media_image2.png 30 242 media_image2.png Greyscale . New/modified rejections are made below, based on Applicant’s amendment of 13 August 2026. In view of Applicant’s amendment of 13 August 2026, the rejections of claims 1, 4-5, 23, 26-27, 33, 35, 37, 51-52, 65 on the ground of nonstatutory double patenting over claims of U.S. patent 10,336,778; over claims of U.S. patent 10,738,066; and over claims of U.S. patent 12,195,419, are herein withdrawn. New/modified rejections are made below, based on Applicant’s amendment of 13 August 2026. Applicant’s amendment of 13 August 2026 necessitated the following new and/or modified objections and rejections below. Claim objection Claims 1, 4-5, 26-27, 33, 35, 37, 45, 51-52, 65 are objected to because they recite a stereoisomer of a compound of formula I. It is noted that the general definition of a “stereoisomer” ([0319] Specification) encompasses all isomers of individual molecules “that differ only in the orientation of their atoms in space”. Since the dependent claims specifically recite enantiomers, for clarity, it is strongly suggested that the claims recite enantiomers or diastereomers of a compound of formula I. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 4-5, 26, 33, 35, 37, 45, 52, 65 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 is indefinite because it recites different substituents without indicating the point of attachment to the molecule. The point of attachment makes a clear difference because it generates different structures. Claim 1, as written, fails to specify points of attachment for PNG media_image3.png 28 466 media_image3.png Greyscale in the definition of R5a. Similarly, there is ambiguity in the definition for R5a in claims 33, 35 regarding the point of attachment of group R5a to the rest of the molecule. It is noted [0050] that R5a (heteroaryl)C1-C4 alkyl is PNG media_image4.png 114 482 media_image4.png Greyscale , which is consistent with R5a being -C1-C4alkyl(heteroaryl), which is consistent with the alkyl being the point of attachment. Appropriate clarification of the claim language is required. Claims 1, 4-5, 26, 37, 45, 52, 65 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 1 recites the broad recitation R5a is “optionally substituted C1-C6 alkyl, optionally substituted aryl”, and the claim also recites “(heterocyclo)C1-C4 alkyl, (aryl)C1-C4 alkyl, (heteroaryl)C1-C4 alkyl” which are the narrower statements of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Appropriate clarification of the claim language is required. Claim 5 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 5 is drawn to PNG media_image5.png 120 672 media_image5.png Greyscale ; yet claim 4, which depends on claim 1, and claim 1 recite that R2 is selected from C1-6 alkyl, C1-C6 haloalkyl, C1-C6 alkenyl, C3-C20 heteroalkyl and C3-C6 cycloalkyl. As such, there is insufficient antecedent basis for the limitation R2 is -CD3, of claim 5, in claim 4 or in claim 1. Appropriate correction is required. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 4-5, 26-27, 33, 35, 37, 45, 51-52, 65 are rejected under 35 U.S.C. 103 as being unpatentable over Slusher et al. (WO 2017/023774, corrected version, cited in PTO-892 of 13 May 2026). Slusher (WO 2017/023774) teaches (page 2, lines 17-30) prodrugs of glutamine antagonists, and salts thereof, and compositions thereof, said prodrugs having a structure of formula (I) PNG media_image6.png 98 268 media_image6.png Greyscale where X is, for example, -CH2-; R1 is, for example, a straight chain alkyl C1-6, or a C1-6 branched alkyl (page 24, lines 1-3); R1 is methyl, or ethyl, or isopropyl (page 24, lines 9-11); R2 is PNG media_image7.png 30 190 media_image7.png Greyscale PNG media_image8.png 52 536 media_image8.png Greyscale (page 38, lines 6-8) where R2’ is, for example, H (page 21, lines 8-9); each R3 or R4 is, for example, H, alkyl, substituted alkyl (page 28, lines 32-33); and R5 and R6 are each, for example, H or alkyl (page 29, lines 1-2). Slusher teaches (page 40, lines 3-6) R2 of formula (I) is PNG media_image9.png 24 182 media_image9.png Greyscale wherein: Y is a bond; m is l; each R3 is independently H, C1-C6 alkyl, or substituted alkyl; each R4 is H; each R5 is independently H, or PNG media_image10.png 22 162 media_image10.png Greyscale each R6 is H, and Slusher exemplifies the following compounds (page 39, first two structures; page 40, line 10) PNG media_image11.png 380 297 media_image11.png Greyscale PNG media_image12.png 206 432 media_image12.png Greyscale . These compounds correspond to compounds of instant formula (I) PNG media_image13.png 132 238 media_image13.png Greyscale for which the following definitions apply: R1 is -OR2, where R2 is C3 alkyl; and R4 is PNG media_image14.png 32 174 media_image14.png Greyscale ; where R5a is substituted alkyl; R6a = H, and R7a is -C1-C4alkyl(amino). Slusher does not teach compounds of instant formula (I) where R7a is PNG media_image2.png 30 242 media_image2.png Greyscale , as in the instant claims. It would have been obvious to prepare a compound from the genus taught by Slusher, with the expectation that the compound is a prodrug of glutamine antagonists. The person of ordinary skill in the art would have synthesized a compound from the genus of compounds of formula (I) taught by Slusher where R2 is PNG media_image7.png 30 190 media_image7.png Greyscale wherein: Y is a bond; m is l; each R3 is independently H, C1-C6 alkyl, or substituted alkyl; each R4 is H; R6 is H; and R5 is PNG media_image10.png 22 162 media_image10.png Greyscale where within R5, R3 = R4 = H and R5 = R6 = methyl or ethyl, with a reasonable expectation that said compounds would retain biological properties as prodrugs of glutamine antagonists. Further, the person of ordinary skill in the art would have replaced the -CH2-CH(CH3)2 substituent or the –(CH2)3-NH-CO-NH2 substituent (corresponding to R5a in instant formula I) in the compounds above taught by Slusher (on pages 39-40), with any other moiety present in an amino acid, such as for example H, or imidazole, or aryl, to arrive at a compound of instant claims 27, 33, 35, because Slusher teaches (page 24, lines 16-28) that R2 comprises an amino acid, natural or non-natural. Further, regarding claim 65, preparing a kit comprising a compound from the genus of Slusher is well within the skill of the artisan. Where the only difference between a prior art product and a claimed product is printed matter that is not functionally related to the product, the content of the printed matter will not distinguish the claimed product from the prior art. In re Ngai, 367 F.3d 1336, 1339, 70 USPQ2d 1862, 1864 (Fed. Cir. 2004) As such, claims 1, 4-5, 26-27, 33, 35, 37, 45, 51-52, 65 are rejected as prima facie obvious. Claims 1, 4-5, 26, 37, 45, 52, 65 are rejected under 35 U.S.C. 103 as being unpatentable over Slusher et al. (WO 2019/071110, cited in IDS). Slusher (WO 2019/071110) discloses [0057] the following compounds, and composition (as in instant claim 52) comprising said compounds, as glutamine antagonists effective to treat oncological, immunological or neurological diseases, PNG media_image15.png 276 422 media_image15.png Greyscale , or [0058] PNG media_image16.png 252 278 media_image16.png Greyscale and where R6 is, for example, one substituted or unsubstituted amino acid [0066], such as, for example, glycine ([0067], Table 2). A substituted amino acid has an amino group which is mono- or disubstituted [0070], such as N-alkyl amino acids, e.g. C1-6 N-alkyl amino acids [0071]. Slusher specifically discloses [0066] the following compounds PNG media_image17.png 604 558 media_image17.png Greyscale , in which R6 is an unsubstituted or substituted amino acid which is tryptophan, phenylalanine, valine or tyrosine (all amino acids in Table 2, [0067]). These compounds correspond to compounds of instant formula (I) PNG media_image13.png 132 238 media_image13.png Greyscale for which the following definitions apply: R1 is -OR2, where R2 is C3 alkyl; and R4 is PNG media_image14.png 32 174 media_image14.png Greyscale ; where R5a is substituted alkyl; R6a = H, and R7a is -C1-C4alkyl(amino). Slusher does not teach compounds of formula (Ig) or (Ih) where R6 is dimethyl glycine, or is diethyl glycine, which correspond to R7a being PNG media_image2.png 30 242 media_image2.png Greyscale in a compound of the instant claims. It would have been obvious to prepare a compound from the genus taught by Slusher, with the expectation that the compound is a prodrug of glutamine antagonists. The person of ordinary skill in the art would have replaced the amino acid moieties R6 tryptophan, phenylalanine, valine or tyrosine in the compounds specifically disclosed in [0066] with glycine, or a dimethyl glycine or a diethyl glycine, because Slusher teaches compounds (Ig) or (Ih) where R6 is an unsubstituted or substituted amino acid, such as glycine, tryptophan, phenylalanine, valine or tyrosine (amino acids in Table 2), unsubstituted or disubstituted, such as C1-6 N-alkyl amino acids. Thus, the person of ordinary skill in the art would have synthesized compounds in which R6 is dimethyl glycine or diethyl glycine, with a reasonable expectation that said compounds have similar biological properties. Further, regarding claim 65, preparing a kit comprising a compound from the genus of Slusher is well within the skill of the artisan. Where the only difference between a prior art product and a claimed product is printed matter that is not functionally related to the product, the content of the printed matter will not distinguish the claimed product from the prior art. In re Ngai, 367 F.3d 1336, 1339, 70 USPQ2d 1862, 1864 (Fed. Cir. 2004) As such, claims 1, 4-5, 26, 37, 45, 52, 65 are rejected as prima facie obvious. Double patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 4-5, 26-27, 33, 35, 37, 45, 51-52, 65 are rejected on the ground of nonstatutory double patenting as being unpatentable at least over claims 1-5, 8, 16 of U.S. patent 10,738,066 (cited in PTO-892 of 13 May 2026, reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because claims anticipate or render obvious the instant claims. Claims 1-5, 8, 16 of U.S. patent 10,738,066 are drawn to a compound of formula PNG media_image18.png 104 254 media_image18.png Greyscale where X is -CH2-; R1 is, for example, methyl, ethyl, isopropyl; R2′ is, for example, H; R2 is, for example, —C(═O)—Y—(CR3R4)m—NR5R6; Y is a bond; m is 1; each R3 and R4 is, for example, H, C1-C6 alkyl, substituted alkyl, each R5 and R6 is, for example, H, alkyl, or —C(═O)—(CR3R4)m—NR5R6. Claim 8 is drawn to the compound of claim 1, where R5 is H and R6 is —C(═O)—(CR3R4)m—NR5R6. Claim 16 is drawn to compounds: PNG media_image19.png 156 236 media_image19.png Greyscale PNG media_image20.png 152 236 media_image20.png Greyscale , which are compounds of claim 1, where X is -CH2-; R1 is ethyl, or isopropyl; R2′ is H; R2 is —C(═O)—Y—(CR3R4)m—NR5R6; Y is a bond; m is 1; each R3 = H; and R4 is C4 alkyl; R5 is H; and R6 is —C(═O)—(CR3R4)m—NR5R6, wherein within R6, R3 is H, R4 is C4 alkyl, R5 = R6 = H. These compounds correspond to compounds of instant formula (I) PNG media_image13.png 132 238 media_image13.png Greyscale for which the following definitions apply: R1 is -OR2, where R2 is C2 or C3 alkyl; and R4 is PNG media_image14.png 32 174 media_image14.png Greyscale ; where R5a is substituted alkyl; R6a = H, and R7a is -C1-C4alkyl(amino). Claims 1-5, 8, 16 of U.S. patent 10,738,066 do not teach a compound of the instant claims where R7a is PNG media_image2.png 30 242 media_image2.png Greyscale . It would have been obvious to prepare a compound from the genus taught by claims 1-5, 8, 16 of U.S. patent 10,738,066 to arrive at the instant invention. The person of ordinary skill in the art would have synthesized a compound from the genus of compounds of formula (I) taught by claims 1-5, 8, 16 of U.S. patent 10,738,066 where R2 is PNG media_image7.png 30 190 media_image7.png Greyscale wherein: Y is a bond; m is l; each R4 is independently H, C1-C6 alkyl, or substituted alkyl; each R3 is H; R6 is H; and R5 is PNG media_image10.png 22 162 media_image10.png Greyscale where within R5, R3 = R4 = H and R5 = R6 = methyl or ethyl, with a reasonable expectation that said compounds would retain biological properties as prodrugs of glutamine antagonists. Further, the person of ordinary skill in the art would have replaced the R4 = -CH2-CH(CH3)2 substituent (corresponding to R5a in instant formula I) in the compounds of claim 16 of U.S. patent 10,738,066, with H, with C1-C6 alkyl or substituted alkyl, because such compounds are within the genus of claim 1 of U.S. patent 10,738,066. Further, regarding claim 65, preparing a kit comprising a compound from the genus of Slusher is well within the skill of the artisan. Where the only difference between a prior art product and a claimed product is printed matter that is not functionally related to the product, the content of the printed matter will not distinguish the claimed product from the prior art. In re Ngai, 367 F.3d 1336, 1339, 70 USPQ2d 1862, 1864 (Fed. Cir. 2004) As such, claims 1, 4-5, 26, 37, 45, 52, 65 are rejected as prima facie obvious. Claims 1, 4-5, 26, 37, 45, 52, 65 are rejected on the ground of nonstatutory double patenting as being unpatentable at least over claims 1, 20, 21, 23, 24 of U.S. patent 12,195,419 (cited in PTO-892 of 13 May 2026). Although the claims at issue are not identical, they are not patentably distinct from each other because claims anticipate or render obvious the instant claims. Claims 1, 20, 21, 23, 24 of U.S. patent 12,195,419 are drawn to a compound of formula below and a composition (as in instant claim 52) comprising said compound, PNG media_image21.png 234 248 media_image21.png Greyscale , where R6 is one or more substituted or unsubstituted amino acids, wherein the one or more substituted or unsubstituted amino acids is bound to the nitrogen atom adjacent to R6 through a carboxyl moiety of the one or more substituted or unsubstituted amino acids; claim 21 lists PNG media_image22.png 572 276 media_image22.png Greyscale PNG media_image23.png 634 610 media_image23.png Greyscale , in which R6 is an unsubstituted or substituted amino acid which is tryptophan, phenylalanine, valine or tyrosine. These compounds correspond to compounds of instant formula (I) PNG media_image13.png 132 238 media_image13.png Greyscale for which the following definitions apply: R1 is -OR2, where R2 is C3 alkyl; and R4 is PNG media_image14.png 32 174 media_image14.png Greyscale ; where R5a is substituted alkyl; R6a = H, and R7a is -C1-C4alkyl(amino). Claims 1, 20, 21, 23, 24 of U.S. patent 12,195,419 do not teach compounds of formula (Ih) of claim 1 where R6 is dimethyl glycine, or is diethyl glycine, which correspond to R7a being PNG media_image2.png 30 242 media_image2.png Greyscale in a compound of the instant claims. It would have been obvious to prepare a compound from the genus taught by claim 1 of U.S. patent 12,195,419 to arrive at the instant invention, to arrive at the instant invention. The person of ordinary skill in the art would have replaced the amino acid moieties R6 tryptophan, phenylalanine, valine or tyrosine in the compounds specifically disclosed in claim 21 of U.S. patent 12,195,419 with glycine, or a dimethyl glycine or a diethyl glycine, because claim 1 of U.S. patent 12,195,419 teaches compounds (Ih) where R6 is an unsubstituted or substituted amino acid. Thus, the person of ordinary skill in the art would have synthesized compounds in which R6 is dimethyl glycine or diethyl glycine, with a reasonable expectation that said compounds retain biological properties. Further, regarding claim 65, preparing a kit comprising a compound from the genus of Slusher is well within the skill of the artisan. Where the only difference between a prior art product and a claimed product is printed matter that is not functionally related to the product, the content of the printed matter will not distinguish the claimed product from the prior art. In re Ngai, 367 F.3d 1336, 1339, 70 USPQ2d 1862, 1864 (Fed. Cir. 2004) As such, the instant claims are rendered obvious by claims 1, 20, 21, 23, 24 of U.S. patent 12,195,419. Conclusion Claims 1, 4-5, 26-27, 33, 35, 37, 45, 51-52, 65 are rejected. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to IRINA NEAGU whose telephone number is (571)270-5908. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JEFFREY S. LUNDGREN can be reached at (571)272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /IRINA NEAGU/Primary Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Oct 27, 2023
Application Filed
May 13, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT
Aug 13, 2026
Response Filed
Oct 26, 2026
Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12768840
METHOD FOR MONITORING AND PREVENTING CLINICALLY SIGNIFICANT KETONE LEVELS IN PATIENTS RECEIVING DICHLOROACETATE CO-ADMINISTERED WITH A CARBOHYDRATE RESTRICTED DIET
1y 5m to grant Granted Oct 20, 2026
Patent 12751937
STABLE LEVOTHYROXINE COMPOSITIONS IN APROTIC POLAR SOLVENTS
2y 11m to grant Granted Oct 06, 2026
Patent 12740955
Treatment or Prevention of Ischaemic Stroke Reperfusion Injury
4y 3m to grant Granted Sep 22, 2026
Patent 12721828
PHARMACEUTICAL LIQUID COMPOSITION, KIT OF PARTS COMPRISING THE PHARMACEUTICAL LIQUID COMPOSITION, AND METHOD FOR PREPARING THE PHARMACEUTICAL LIQUID COMPOSITION
4y 4m to grant Granted Sep 01, 2026
Patent 12685721
AEROSOL COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE
3y 11m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
47%
Grant Probability
99%
With Interview (+57.2%)
2y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 720 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month